Pharmacovigilance Dr. SURENDRA.S.AKASH MD.

Slides:



Advertisements
Similar presentations
10/20/ The Pharmaceutical Industry and Their Influence on Pain Management in the ED J. David Haddox, DDS, MD VP, Risk Management & Health Policy.
Advertisements

Safety Reporting IN Clinical Trials
Sevene E, Mariano A, Mola D Faculty of Medicine / Ministry of Health Pretoria, September 2004 PHARMACOVIGILANCE SYSTEM - MOZAMBIQUE INTRODUCING PV INTO.
Walsall Healthcare NHS Trust Medicines Management.
Technical Briefing Seminar September |1 | The need for Pharmacovigilance Mary R Couper and Shanthi Pal Quality Assurance and Safety of Medicines.
Clinical Pharmacist Intervention in Cardiac Patients With Renal Impairment Elham Al-Shammari, B.Sc. Pharm. Hisham Abou-Auda, Ph. D. Meshal Al-Mutairi,
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.
Clinical Pharmacy Basma Y. Kentab MSc..
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Role of Pharmacist in Malaria Control
 Pharmacovigilance – Patient’s standpoint Steve Arlington May 2007.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Isah, Ambrose Ohumagho (1); Pal, Shanthi (2); Olsson, Sten (3)
Pharmacovigilance Programme of India
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
WORD GOD END’S WITH ALPHABET "D“ WORD DRUG END’S WITH ALPHABET "G"
Application of Pharmacovigilance in post- marketing traditional Chinese medicine Hua-Wen Xin Wuhan General Hospital, Wuhan, China.
Pharmacy and Poisons Board Pharmacy and Poisons Board, Kenya Role of Regulation in Optimizing Medicine use KNH/UON Pharmacy Symposium Optimizing Medicine.
ACCESS TO MEDICINES - POLICY AND ISSUES
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
Technical Briefing Seminar September |1 | Methods to study medicine safety problems Mary R Couper Quality Assurance and Safety of Medicines.
Dr Shanthi Pal Quality Assurance and Safety of Medicines WHO
In the early 1900 s Paul Ehrlich described an ideal drug as a magic bullet. magic bullet. Such a drug would be aimed precisely at a disease site and would.
The Dilemma of Diclofenac Injection for the Iranian Health System Authors: Shalviri G, Cheraghali M, Gholami K, Kamali E, Daryabari N Institution: Ministry.
PV of ARVs, November 2009, Dar Es Salaam 1 |1 | The need for Pharmacovigilance Shanthi Pal Quality Assurance and Safety of Medicines.
Dr Mary Couper Quality Assurance and Safety of Medicines WHO
Pharmacovigilance WHO definition
Minimum requirements for Pharmacovigilance in countries.
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
PHARMACOVIGILANCE PLAN FOR TANZANIA PREPARED BY EMMA & MARY 10 TH SEPTEMBER 2004.
1 Pharmacovigilance & the New National Adverse Drug Reaction (ADR) Reporting System Michael Bonett, Quality Assessor Post-Licensing Directorate Medicines.
Why do we need Pharmacovigilance?
Medication therapy management
Off-label Use.
Social Pharmacy and Pharmacovigilance
Detection & monitoring of ADR
Efficacy and Safety of Medicines
Why do we need Pharmacovigilance?
به نام و یاد خالق هستی هم او که آفرید شور و مستی.
World Health Organization
Assessing expectedness of an adverse event
EudraVigilance.
The Many Careers of Pharmacy
8. Causality assessment:
Pharmacovigilance: Tool for safe medication
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Introduction to Clinical Pharmacy
Pharmacovigilance in clinical trials
9. Introduction to signal detection
Quality Assurance and Safety of Medicines
Developing pharmacovigilance: new challenges and opportunities Mary Couper and Shanthi Pal Quality Assurance and Safety of Medicines.
Medication Safety Dr. Kanar Hidayat
Pharmacovigilance (PV)
SERIOUS ADVERSE EVENTS REPORTING
به نام و یاد خالق هستی هم او که آفرید شور و مستی.
68.3 million errors (28% of total) cause moderate or serious harm
Pharmacovigilance What? (2.6) Ensure ADR monitoring (Spontaneous reporting/Cohort studies) Who? Healthcare workers How? WHO International Drug Monitoring.
Pharmacovigilance & Adverse Drug Reactions Dr. Habab Khalid Elkheir
Pharmacy practice experience I
Pharmacovigilance Systems: Drug Safety Surveillance
Medicines Safety Mary R. Couper
Medicines Safety Programme
Medication Safety Dr. Kanar Hidayat
Tobey Clark, Director*, Burlington USA
Quality Assurance and Safety of Medicines
Medical Device Safety: India’s Perspective
Pharmacovigilance.
Presentation transcript:

Pharmacovigilance Dr. SURENDRA.S.AKASH MD

We define an adverse drug reaction as "an appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which predicts hazard from future administration and warrants prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the product." ADVERSE DRUG REACTION 12.09.2018

The science and activities relating to the detection, evaluation, understanding and prevention of adverse drug reactions or any other drug-related problems Pharmacovigilance

Aims of Pharmacovigilance To improve patient care and safety To improve public health and safety To contribute to the assessment of benefit, harm, effectiveness and risk of medicines To promote understanding, education and clinical training Aims of Pharmacovigilance

Who are the partners? Government Industry Hospitals and academia Medical and pharmaceutical associations Poisons information centres Health professionals Patients Consumers Media WHO Who are the partners?

1986 - a formal adverse drug reaction (ADR) monitoring system consisting of 12 regional centers, each covering a population of 50 million, was proposed for India. In 1989, under the aegis of the Drug Controller of India, six regional centres were set up in Mumbai, New Delhi, Calcutta, Lucknow, Pondicherry and Chandigarh. History

12.09.2018

In 1997, India joined the WHO Programme for International Drug Monitoring managed by the Uppsala Monitoring Centre, Sweden. Of the six centres, only the centres in Mumbai and New Delhi were active, yet spontaneous reporting of ADRs was poor.

Recognising the need for improved ADR monitoring in India, the Government of India sent a proposal to the World Bank for funding. The World Bank approved the proposal with an annual grant of $US 0.1 million for 5 years and the National Pharmacovigilance programme was launched in November 2004. History

Why do we need pharmacovigilance?

1959 / 61– Epidemia de focomelia por Talidomida (4. 000 – 10 1959 / 61– Epidemia de focomelia por Talidomida (4.000 – 10.000 casos no mundo, com 15% de mortos)

Reason 1: Humanitarian concern – Insufficient evidence of safety from clinical trials Animal experiments Phase 1 – 3 studies prior to marketing authorization Reason 1:

Examples of product recalls due to toxicity MEDICINE YEAR Examples of serious and unexpected adverse events leading to withdrawal of medicine Thalidomide 1965 Phocomelia Practolol 1975 Sclerosing peritonitis Terfenadine 1997 Torsade de pointes Rofecoxib 2004 Cardiovascular effects Veralipride 2007 Anxiety, depression, movement disorders Rosiglitazone 2010 Nimesulide 2011 Hepatotoxicity Examples of product recalls due to toxicity

Reason 2 Medicines are supposed to save lives Dying from a disease is sometimes unavoidable; dying from a medicine is unacceptable. Lepakhin V. Geneva 2005 Reason 2

More than 3% of all deaths seem to be caused by adverse reactions to medical drugs, according to new research.

Warfarin, Insulin and Digoxin are the most Dangerous drugs in the elderly. Do we believe that?

ADRs are expensive !! 6.5% of admissions are due to ADRs Reason 3

Cost of drug related morbidity and mortality exceeded $177 Cost of drug related morbidity and mortality exceeded $177.4 billion in 2000 (Ernst FR & Grizzle AJ, 2001: J American Pharm. Assoc) ADR related cost to the country exceeds the cost of the medications themselves Cost of ADRs in the US?

Promoting rational use of medicines and adherence Reason 4:

Prescription problems

Ensuring public confidence Reason 5

According to a fact sheet by WHO(May-2010) about the rational use of medicines ,more than 50 percent of all medicines are not correctly prescribed ,dispensed, and sold: and more than 50 percent patients take their drugs incorrectly.

Ethics To know of something that is harmful to another person who does not know, and not telling, is unethical Reason 6

Not reporting a serious unknown reaction is unethical valid for everyone patient health professional manufacturer authorities

ADR FORM

ADR FORM

What to report? The programme particularly solicits reports of: • All adverse events suspected to have been caused by new drugs and ‘drugs of current interest' (List published by CDSCO {Central Drugs Standard Control Organization} from time to time) What to report?

• Reactions to any other drugs which are suspected of significantly affecting a patient's management, including reactions suspected of causing: • Death • Life-threatening (real risk of dying) • Hospitalization (initial or prolonged) • Disability (significant, persistent or permanent) • Congenital anomaly • Required intervention to prevent permanent impairment or damage.

WHO Programme for International Drug Monitoring

National PVig Programme

PSG INSTITUTE,TAMILNADU AIIMS newdelhi Travancore Medical college Ministry of Health India UMC Sweden WHO-HQ Geneva

12.09.2018

12.09.2018

SEND NOT ONLY QUANTITY BUT…. SO….WHAT IS OUR ROLE?

HOW? Monitor clinical status of patients Identify the correct ADRs not side effects Get more information Investigate at hospital level Help practitioners to fill-up the forms Keep patient’s record if more information needed HOW?

Pharmacovigilance looks at all available information to assess the safety profile of a drug. Pharmacovigilance should also take the benefit of the drug in account. Pharmacovigilance is required for systematically identifying and correlating drugs and side-effects and taking corrective actions, especially for the product launching first time in India. CONCLUSION

THANKYOU

Tegaserod is reported to increase the risk of heart attacks by 10 times, while the use of gatifloxacin in elderly patients may increase risk of developing serious hyperglycemia 17 times compared with other anti-biotics